WASHINGTON, July 14 (KUNA) -- The US biotech company Moderna's coronavirus vaccine has shown 'promising' safety and immune response results in the first stage according to a new study.
These early results, published in the New England Journal of Medicine on Tuesday, showed that the vaccine worked to trigger an immune response with mild side effects -- fatigue, chills, headache, muscle pain, pain at the injection site --, reported the CNN today.
It clarified that the vaccine is expected to begin on July 27 Phase three trial -- the final trial stage before regulators consider whether to make the vaccine available.
It is expected to be the first in the United States to begin Phase 3 trials. The company has started Phase two late May.
Moderna noted in a press release on Tuesday that, if all goes well in future studies, "the Company remains on track to be able to deliver approximately 500 million doses per year, and possibly up to 1 billion doses per year, beginning in 2021." (end)